Elevance holds benefit expense ratio guidance above 90% as fall renewals approach

# Overview Elevance Health told investors it is holding full-year 2026 benefit expense ratio guidance at 90.2 percent, plus or minus 50 basis points, in an 8‑K filed with the SEC on September 10, 2026. The company also said it will meet with investors and analysts and reaffirm adjusted earnings guidance of at least $27 per diluted share.

# What the benefit expense ratio measures A benefit expense ratio of 90.2% means Elevance expects to pay roughly 90 cents of every premium dollar in medical claims. That leaves a narrow margin to cover administrative costs, taxes, and profit. The company's Q2 2026 ratio was 89.7% — up 80 basis points year over year — which underpins the decision to keep full‑year guidance elevated.

# Why the ratio is elevated The drivers called out in Elevance's disclosures are consistent with earlier earnings commentary:

• Specialty pharmacy. Costs for specialty drugs, particularly GLP‑1 medications, have been highlighted throughout 2026. Pharmacy claims are processed through Elevance's Carelon subsidiary, and specialty pharmacy dynamics have been among the few offsets to higher medical costs.
• Seasonal pattern. Elevance's guidance implies the second half of 2026 will run heavier than the first, with Q4 historically the highest‑cost quarter.

# What this means for fall group renewals Insurance carriers set renewal rates based on expected claims. By reaffirming a 90.2% benefit expense ratio and signaling heavier second‑half costs, Elevance is effectively confirming it has budgeted for substantial claims payouts and will price renewals with that expectation in mind. For brokers and employers:

• Negotiating leverage is constrained. Public disclosures show claims running at the top of the company's expected range, so Elevance has justification for higher renewal pricing.
• Rate increases are likely to reflect the same cost pressures seen across the market. Group health insurer margins thinned across the employer segment in 2025, with MFA data showing medical expenses grew 8.6% per member per month while premiums grew 6.6%.

# Practical next steps for brokers and employers Brokers preparing for fall renewals should:

• Review claims experience and plan design levers now, focusing on specialty pharmacy management and utilization controls.
• Benchmark Elevance renewal proposals against market alternatives, especially if specialty drug exposure or Medicaid‑like acuity is concentrated in the book of business.
• Prepare documentation showing plan performance and any targeted clinical or pharmacy interventions that could support rate moderation.

Employers should expect renewal offers that reflect elevated medical and specialty pharmacy trends and be ready to discuss targeted cost‑management options with their broker.

# Bottom line Elevance's reaffirmation of a benefit expense ratio above 90% is a clear market signal: medical and specialty pharmacy costs are running at the high end of expectations, and the carrier has priced fall renewals accordingly. Brokers and employers should treat renewal conversations as negotiations where the carrier's public data validates higher claims experience rather than as a softening of cost pressure.